Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/4/?d=1Neue Studien: Europe PMCdeIntegrating network pharmacology and experimental validation to elucidate the mechanism of Xiao-bi decoction in psoriasis treatment: Inhibition of JAK2/STAT3 signaling and rebalancing Th17/Treg responses.https://www.psoriasis-news.de/articles.html/1_articles/integrating-network-pharmacology-and-experimental-validation-to-elucidate-the-mechanism-of-xiao-bi-decoction-in-psoriasis-treatment-inhibition-of-jak2stat3-signaling-and-rebalancing-th17treg-responses-r515/Ethnopharmacological relevanceThe traditional Chinese herbal medicine called Xiao-bi decoction (XBD) has been used for decades to treat psoriasis, but its mechanism of action is poorly understood.

Aim of the study

To investigate the underlying mechanism of XBD against psoriasis using systematic pharmacological techniques.

Materials and methods

A psoriasis model was established in mice using imiquimod (IMQ). The efficacy of XBD was evaluated based on psoriasis severity scores and immune cell infiltration. Core components and targets were screened using UPLC-QE-MS/MS and network pharmacology. The mechanism was further explored via transcriptome sequencing, ELISA, western blotting, immunolocalization, and molecular docking.

Results

XBD treatment significantly alleviated IMQ-induced psoriatic symptoms like erythema, scaling, and thickening. It reduced CD4+ T cell infiltration in skin and decreased serum levels of IL-17, IL-1β, IL-23, and IL-36. XBD specifically decreased CD4+-IL-17+ cells while increasing CD4+-FoxP3+ cells in both blood and skin. A total of 1223 chemical components were identified in XBD, including 78 blood-entering components. Network pharmacology and transcriptome analysis collectively demonstrate that XBD inhibits the activation of the JAK2/STAT3 signaling pathway, indicating its potential role in modulating this pathway. Our results also showed that XBD modulated Th17/Treg balance in serum and ameliorating skin inflammation in IMQ-induced psoriatic model.

Conclusion

The herbal medicine Xiao-bi decoction may regulate the JAK2/STAT3 pathway, thereby influencing the Th17 response and Treg differentiation, and thereby alleviating the skin inflammation of psoriasis.

Weiterlesen

]]>515Wed, 11 Mar 2026 15:51:58 +0000Baseline Clinical and Metabolic Predictors of 52-Week Durability of Secukinumab Response in Moderate-to-Severe Plaque Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/baseline-clinical-and-metabolic-predictors-of-52-week-durability-of-secukinumab-response-in-moderate-to-severe-plaque-psoriasis-r514/BackgroundDurability of response to IL-17A blockade (secukinumab) varies, representing a major clinical challenge. Psoriasis is inherently linked to immunometabolic dysfunction. We hypothesized that simple, routine metabolic indices could predict long-term treatment stability, offering crucial pre-treatment stratification tools.

Methods

This was a 52-week prospective, single-center cohort study of 118 patients with moderate-to-severe plaque psoriasis initiating secukinumab. We defined Durable Response (DR) as PASI90 at Week 12 maintained as absolute PASI ≤ 2 until Week 52. Multivariable logistic regression and Cox models were used to identify independent predictors of DR and drug survival.

Results

Independent predictors of durable response were biologic-naïve status (adjusted OR = 3.52, 95% CI: 1.58-7.85) and a lower baseline TG/HDL-C ratio (adjusted OR = 0.61, 95% CI: 0.47-0.79). Conversely, obesity (BMI≥30) (OR = 0.42) and higher baseline PASI (OR = 0.91) were associated with reduced odds of DR. Conventional systemic inflammatory markers (CRP, NLR) showed no significant difference. Drug survival was significantly higher in DRs (92.6% vs 78.3% at Week 52) and was independently reduced by psoriatic arthritis.

Conclusion

The routine baseline TG/HDL-C ratio is a strong, independent predictor of sustained secukinumab efficacy. These easily accessible clinical and metabolic features capture the immunometabolic milieu influencing IL-17A inhibition durability. Integrating the TG/HDL-C ratio into pre-treatment assessment can support patient stratification and optimize long-term management strategies for plaque psoriasis.

Weiterlesen

]]>514Wed, 11 Mar 2026 15:51:58 +0000The Emerging Role of Gut Microbiota in Inflammatory Skin Diseases: A Systematic Review.https://www.psoriasis-news.de/articles.html/1_articles/the-emerging-role-of-gut-microbiota-in-inflammatory-skin-diseases-a-systematic-review-r513/Weiterlesen

]]>513Wed, 11 Mar 2026 15:51:58 +0000PBMC transcriptomic signatures reflect immune dynamics and disease activity in psoriatic arthritishttps://www.psoriasis-news.de/articles.html/1_articles/pbmc-transcriptomic-signatures-reflect-immune-dynamics-and-disease-activity-in-psoriatic-arthritis-r512/No abstract supplied.

Weiterlesen

]]>512Wed, 11 Mar 2026 15:51:58 +0000Letter From the New Editor-in-Chiefhttps://www.psoriasis-news.de/articles.html/1_articles/letter-from-the-new-editor-in-chief-r511/No abstract supplied.

Weiterlesen

]]>511Wed, 11 Mar 2026 15:51:58 +0000Determinants of Quality of Life and Mental Health in Kenyan Psoriasis Patients: A Cross-Sectional Analysis from the Kenyan Psoriasis Registryhttps://www.psoriasis-news.de/articles.html/1_articles/determinants-of-quality-of-life-and-mental-health-in-kenyan-psoriasis-patients-a-cross-sectional-analysis-from-the-kenyan-psoriasis-registry-r510/No abstract supplied.

Weiterlesen

]]>510Wed, 11 Mar 2026 15:51:58 +0000Real-World Effectiveness and Safety of Tapinarof 1% Cream in Psoriasis: An Observational Study From Bangladeshhttps://www.psoriasis-news.de/articles.html/1_articles/real-world-effectiveness-and-safety-of-tapinarof-1-cream-in-psoriasis-an-observational-study-from-bangladesh-r509/No abstract supplied.

Weiterlesen

]]>509Wed, 11 Mar 2026 15:51:58 +0000Bone properties and biomechanics in patients with psoriatic disease: a cross-sectional study with high-resolution peripheral quantitative CT (HRpQCT).https://www.psoriasis-news.de/articles.html/1_articles/bone-properties-and-biomechanics-in-patients-with-psoriatic-disease-a-cross-sectional-study-with-high-resolution-peripheral-quantitative-ct-hrpqct-r505/BackgroundPsoriatic disease has a complex effect on bone metabolism, resulting in both pathological bone formation and bone resorption. However, microstructural changes in cortical and trabecular compartments remain poorly understood. The aim of this study was to investigate the prevalence and determinants of bone microarchitectural damage in patients with psoriatic disease.

Methods

We performed a cross-sectional study in patients with psoriasis (PsO), psoriatic arthritis (PsA) and age-matched healthy controls (HCs) recruited into the Department of Dermatology and Rheumatology of Verona centre. We conducted high-resolution peripheral quantitative CT of the radius and finger joints of the non-dominant hand. Bone microstructure parameters and finite element analysis (uFEA) were calculated.

Results

51 patients with PsO and 39 patients with PsA were consecutively enrolled in the study. 24 age-matched HCs were enrolled. Distal radius total and cortical volumetric bone mineral density (Ct.BMD) levels were lower in patients with PsA and PsO compared with HC. On distal radius uFEA analysis, we found a significant reduction of stiffness in PsA compared with both HC and PsO. At the distal interphalangeal (DIP) joints, Ct.BMD and trabecular volumetric bone mineral density were lower in PsA and PsO compared with HC. Nail involvement in psoriatic disease was negatively associated with bone stiffness at the proximal and distal region of the DIPs.

Conclusion

Psoriatic disease negatively impacted bone integrity. Patients with psoriatic disease seemed to have lower bone density and more microarchitectural alteration that impacted on biomechanics properties. Nail involvement was associated with decreased bone stiffness in psoriatic disease.

Weiterlesen

]]>505Wed, 11 Mar 2026 05:52:24 +0000Isolinderalactone targets TNF-α/STAT3 inflammatory pathways to attenuate psoriasis-like dermatitis.https://www.psoriasis-news.de/articles.html/1_articles/isolinderalactone-targets-tnf-%CE%B1stat3-inflammatory-pathways-to-attenuate-psoriasis-like-dermatitis-r504/BackgroundGiven the proinflammatory cascade elicited by tumor necrosis factor-α (TNF-α) in psoriasis, multiple TNF-α-targeted biologics have been developed for psoriasis treatment. Although systemic macromolecular biologics are widely used, a crucial therapeutic gap remains for mild-to-moderate psoriasis, underscoring an unmet need for more effective topical drugs suppressing TNF-induced inflammatory signaling.

Objective

To identify a novel potent natural small-molecule drug suppressing TNF-induced inflammatory signaling and elucidate its therapeutic mechanism in psoriasis.

Methods

First, candidate small-molecule drugs were screened out through a high-throughput screening platform. Next, the therapeutic effect of Isolinderalactone was evaluated through topical application in the imiquimod (IMQ)-induced psoriasis-like mouse model. Subsequently, RNA sequencing (RNA-seq) analysis of TNF-α-stimulated HaCaT cells and epidermis of IMQ-treated mice identified key transcriptomic alterations induced by Isolinderalactone treatment. Finally, anti-psoriasis effects and underlying mechanisms of Isolinderalactone were verified in both in vivo and in vitro experiments.

Results

Isolinderalactone was identified as a potent drug suppressing TNF-related signaling with low cytotoxicity. Topical application of Isolinderalactone significantly alleviated IMQ-induced psoriasis-like dermatitis. Conjoint analysis of RNA-seq for TNF-α-stimulated HaCaT cells and epidermis from lesions of IMQ-treated mice revealed Isolinderalactone downregulated the expression of TNF-α, interleukin-17 (IL-17) and S100-related inflammatory factors in epidermal keratinocytes. Mechanistically, Isolinderalactone significantly inhibited the TNF-α/STAT3 inflammatory pathways in epidermal keratinocytes and exerted an anti-inflammatory effect.

Conclusion

Isolinderalactone exhibits anti-inflammatory activity through multiple mechanisms, highlighting the potential of topical Isolinderalactone therapy for mild-to-moderate psoriasis.

Weiterlesen

]]>504Wed, 11 Mar 2026 05:52:24 +0000Validation of performance of Spanish version of PURE-4 questionnaire for early identification of psoriatic arthritis after 1 year of follow-up in patients with psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/validation-of-performance-of-spanish-version-of-pure-4-questionnaire-for-early-identification-of-psoriatic-arthritis-after-1-year-of-follow-up-in-patients-with-psoriasis-r503/Background and objectivePsoriatic arthritis (PsA) is an inflammatory, chronic and progressive musculoskeletal disease associated with psoriasis. The validation of the Spanish version of the Psoriatic arthritis UnclutteRed screening Evaluation (PURE-4) questionnaire has been published previously. The present analysis studied the performance of the PURE-4 questionnaire for the early detection of PsA one year before its diagnosis.

Materials and methods

This was an observational multicenter study, including two cross-sectional assessments, with primary data collection in routine clinical practice in Spain. Adult patients with psoriasis and confirmed not having PsA diagnosis during Assessment I completed Assessment II by the rheumatologist one year (±2 months) after answering the PURE-4 questionnaire. This work presents the results of Assessment II, to confirm/rule out the presence of PsA in patients with psoriasis one year after PURE-4 answering. The analysis, involving the results from Assessment II, will evaluate the performance of the PURE-4 questionnaire for the early detection of potential PsA in terms of sensitivity and specificity.

Results

There were 219 evaluable patients, 56.2% male, and the mean (standard deviation [SD]) age was 46.8 (12.5) years. At one year, the PsA diagnosis was confirmed in 12 (5.5%) patients, representing 26.1% of the total number of patients with PsA diagnosed since the beginning of the study. The mean (SD) PURE-4 score was 2.4 (1.1) for patients with PsA and 1.2 (1.2) for patients without a diagnosis of PsA (p = 0.0016). The area under the receiver-operating characteristic (ROC) curve confirmed the good quality of the questionnaire (0.7618; 95% CI: 0.6530-0.8706; n = 217). PURE-4 showed a sensitivity of 75.0% and a specificity of 62.9%.

Conclusions

The PURE-4 questionnaire offers good clinimetric capabilities for the early detection of PsA with a score ≥2. Of the total number of patients with PsA, one in four were detected one year after answering positively to the questionnaire, which would help to predict which patients are at high risk of developing PsA. The authors reinforce the recommendation to closely follow up with these patients.

Weiterlesen

]]>503Wed, 11 Mar 2026 05:52:24 +0000Association Between Inflammatory Cytokines and Systemic Inflammation Indices in Patients With Psoriasis: A Cross-Sectional Study.https://www.psoriasis-news.de/articles.html/1_articles/association-between-inflammatory-cytokines-and-systemic-inflammation-indices-in-patients-with-psoriasis-a-cross-sectional-study-r502/Background and objectivesSystemic inflammation indices derived from complete blood counts (CBC) are accessible markers of inflammatory burden, but their relationship with circulating cytokines in psoriasis remains unclear. We investigated associations between CBC-derived indices and serum cytokines in psoriasis.

Materials and methods

In this cross-sectional study, we included 28 patients with psoriasis and 23 healthy controls. Serum IL-17, IL-22, IL-23, IL-31, IL-33, IL-36, TNF-α, TGF-β, and IFNγ were quantified by ELISA. CBC-derived indices were computed (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune-inflammation value (PIV). Case-control comparisons used the full sample. Cytokine-index associations were evaluated in psoriasis patients using bivariate correlations and multivariate GLM adjusted for age, smoking, and NAFLD. Multiplicity was controlled using Benjamini-Hochberg false discovery rate (BH-FDR); prespecified sensitivity analyses used log-transformed cytokines and Spearman correlations.

Results

Psoriasis patients had higher levels of all cytokines (all p < 0.001) and higher SIRI versus controls (p < 0.001; q = 0.005). PIV showed a nominal case-control difference (p = 0.022) that did not remain significant after BH-FDR (q = 0.055), while NLR, PLR, and SII did not differ. In adjusted multivariate GLM, TGF-β showed a global association with the joint set of indices (Pillai's trace = 0.295; p = 0.039) that did not survive BH-FDR (q = 0.507) and was attenuated with log-transformation. Nominal univariate effects for TNF-α on SIRI (F = 4.600; p = 0.039) and PIV (F = 5.660; p = 0.023) did not remain significant after BH-FDR.

Conclusions

SIRI was consistently elevated in psoriasis, whereas PIV showed a nominal difference versus controls. Across exploratory analyses, SIRI and PIV showed the most consistent directional co-variation with cytokines, but associations were modest. These findings are hypothesis-generating and support further validation in larger cohorts to determine whether CBC-derived indices can serve as scalable adjunct markers of inflammatory activity in psoriasis.

Weiterlesen

]]>502Wed, 11 Mar 2026 05:52:24 +0000Transcriptomic Analysis of Differentially Expressed Lipid Metabolism-Related Genes in Psoriasis Patientshttps://www.psoriasis-news.de/articles.html/1_articles/transcriptomic-analysis-of-differentially-expressed-lipid-metabolism-related-genes-in-psoriasis-patients-r501/Psoriasis, a chronic and recurring disease, is closely associated with lipid metabolism. This study aims to identify differentially expressed genes (DEGs) and their functional pathways associated with psoriasis to uncover new therapeutic targets. We leveraged Gene Expression Omnibus (GEO) datasets for DEGs analysis in psoriasis. Gene Set Enrichment Analysis (GSEA), Gene Set Variation Analysis (GSVA), Weighted Gene Co-expression Network Analysis (WGCNA), and single-sample GSEA (ssGSEA) were used to investigate the roles of lipid metabolism genes in psoriasis progression and immune alterations. An RBP-mRNA network revealed post-transcriptional regulatory mechanisms. Our findings revealed 3,839 DEGs, including 1,775 upregulated and 2,064 downregulated genes in psoriatic samples compared to controls. Enrichment analysis showed that immune-related pathways such as cytoplasmic DNA sensing pathways and NOD-like receptor signaling pathways were significantly enriched. WGCNA identified modules highly correlated with lipid metabolism and screened out key genes such as AACS, HSD11B1 and GATA6. ROC curve analysis showed that these genes had a high discriminatory ability (AUC > 0.85) within the analyzed dataset, suggesting their potential as novel biomarkers. Immune infiltration analysis revealed significant differences in 27 types of immune cells between patients with psoriasis and the control group. This study provides new clues for the molecular mechanism of psoriasis and potential therapeutic targets.

Weiterlesen

]]>501Wed, 11 Mar 2026 05:52:24 +0000Correction: Ketogenic diet improves disease activity and cardiovascular risk in psoriatic arthritis: A proof of concept study.https://www.psoriasis-news.de/articles.html/1_articles/correction-ketogenic-diet-improves-disease-activity-and-cardiovascular-risk-in-psoriatic-arthritis-a-proof-of-concept-study-r500/Weiterlesen

]]>500Wed, 11 Mar 2026 05:52:24 +0000Real-World Burden of Generalized Pustular Psoriasis in a French Observational Study: Prevalence, Incidence, Healthcare Resource Utilization, Comorbidities, Treatment Use, and Mortality.https://www.psoriasis-news.de/articles.html/1_articles/real-world-burden-of-generalized-pustular-psoriasis-in-a-french-observational-study-prevalence-incidence-healthcare-resource-utilization-comorbidities-treatment-use-and-mortality-r499/IntroductionGeneralized pustular psoriasis (GPP) is rare, chronic, and associated with life-threatening complications. We investigated the burden of GPP in France.

Methods

Using data from 2010 to 2021 in the Système National des Données de Santé database, healthcare resource utilization (HCRU), costs, comorbidities, mortality, and treatments were compared among GPP (N = 4351), plaque psoriasis (N = 12,945), and general population (N = 12,981) cohorts, matched for sex, age, Charlson Comorbidity Index (CCI) score, and region. GPP prevalence and incidence were also investigated.

Results

Annually, there were 0.5-0.8 new GPP cases per 100,000 people. Across the cohorts, 54.5-54.7% of people were male, with mean age 58.7-59.5 years and mean CCI score 1.98-2.06. The GPP cohort incurred significantly greater HCRU and costs versus the plaque psoriasis and general population cohorts, including greater proportions of patients receiving emergency care (78% vs 63% and 55%) and intensive care (28% vs 17% and 14%), longer hospitalizations (mean 38.5 vs 26.2 and 22.4 days per patient), and higher medication costs (€4360 vs €1991 and €1543 per patient-year), respectively. Despite similar CCI scores, GPP was associated with more cardiometabolic and psychological comorbidities versus the plaque psoriasis and general population cohorts, e.g., hypertension (37% vs 21% and 20%), obesity (21% vs 9% and 6%), depression (13% vs 4% and 4%), alcohol abuse (16% vs 3% and 3%), and sleep disorders (8% vs 4% and 3%), respectively. Treatments in the GPP cohort were those used for plaque psoriasis, including topical steroids (77%), systemic steroids (50%), and biologics (23%). Twelve-month survival was 86.9% (GPP), 97.5% (plaque psoriasis), and 90.0% (the general population).

Conclusion

HCRU, costs, and comorbidities with GPP were often double those for comparator cohorts, and mortality was higher. These findings highlight the need to use GPP-targeted treatments that improve patient outcomes and may reduce the burden on healthcare systems.

Weiterlesen

]]>499Wed, 11 Mar 2026 05:52:24 +0000TLR9/MyD88/NF-κB signaling mediates mental stress-induced exacerbation of psoriasis through immune dysregulation in a mouse model.https://www.psoriasis-news.de/articles.html/1_articles/tlr9myd88nf-%CE%BAb-signaling-mediates-mental-stress-induced-exacerbation-of-psoriasis-through-immune-dysregulation-in-a-mouse-model-r498/ObjectivePsoriasis is a chronic inflammatory autoimmune disease that affects physical and mental health. Mental stress has been shown to exacerbate human psoriasis by unknown mechanism.

Methods

Peripheral blood mononuclear cells (PBMCs) were collected from patients with psoriasis and mental stress-treated psoriatic mice. The expression levels of TLR9/MyD88/NF-κB pathway-related molecules were analyzed by qRT-PCR and western blotting. Histological examination of skin lesions was examined using hematoxylin-eosin staining. The ratios of Treg/CD4+T cells and Th17/Treg cells were determined by flow cytometry. The associations among mental stress, the TLR9/MyD88/NF-κB pathway, and psoriasis were explored using pharmacological inhibitors and lentiviral transfection.

Results

Our findings demonstrated a significant upregulation of TLR9/MyD88/NF-κB pathway-associated molecules in the PBMCs of psoriasis patients, accompanied by elevated expression of inflammatory factors. These observations were validated using a mouse model of psoriasis. Notably, mental stress was shown to activate the TLR9/MyD88/NF-κB pathway and enhance inflammatory factor production, while simultaneously increasing the Th17/Treg ratio and decreasing the Treg/CD4+T ratio. Therapeutic interventions including antipsychotic sertraline, pathway-specific inhibitors, and lentiviral transfection significantly ameliorated inflammatory markers and improved psoriasis severity grading.

Conclusion

The results of this study demonstrates that mental stress induces inflammation and immune dysregulation, exacerbating psoriasis progression. These findings provide valuable insights into the pathophysiological mechanisms underlying psoriasis progression, particularly the mental stress-mediated immunoregulatory axis.

Weiterlesen

]]>498Wed, 11 Mar 2026 05:52:24 +0000Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.https://www.psoriasis-news.de/articles.html/1_articles/bimekizumab-efficacy-in-scalp-nail-and-palmoplantar-psoriasis-versus-comparators-and-over-4-years-r497/Trial registrationBE SURE (NCT03412747), BE VIVID (NCT03370133), BE RADIANT (NCT03536884), BE READY (NCT03410992), BE BRIGHT (NCT03598790).

Weiterlesen

]]>497Wed, 11 Mar 2026 05:52:24 +0000Psoriasis-like disease prevents squamous skin tumor development by neutrophil-driven inflammation.https://www.psoriasis-news.de/articles.html/1_articles/psoriasis-like-disease-prevents-squamous-skin-tumor-development-by-neutrophil-driven-inflammation-r496/Weiterlesen

]]>496Wed, 11 Mar 2026 05:52:24 +0000Biological Treatment of Psoriasis-Data So Far.https://www.psoriasis-news.de/articles.html/1_articles/biological-treatment-of-psoriasis-data-so-far-r495/Weiterlesen

]]>495Sat, 28 Feb 2026 14:57:08 +0000'Thousand counties, no psoriasis': A public-health pathway to early psoriasis care in China.https://www.psoriasis-news.de/articles.html/1_articles/thousand-counties-no-psoriasis-a-public-health-pathway-to-early-psoriasis-care-in-china-r494/No abstract supplied.

Weiterlesen

]]>494Sat, 28 Feb 2026 14:57:08 +0000Increased Risk of Incident Uveitis Among Patients with Psoriasis: A Nationwide Population-Based Cohort Study.https://www.psoriasis-news.de/articles.html/1_articles/increased-risk-of-incident-uveitis-among-patients-with-psoriasis-a-nationwide-population-based-cohort-study-r493/Background: Psoriasis is a chronic systemic inflammatory disease with established extra-cutaneous manifestations. While the association between uveitis and spondyloarthritis (SpA)-related disorders is well recognized, the incident risk of uveitis among broader psoriasis populations remains inadequately defined due to methodological limitations and inconsistent findings across previous studies. We aimed to estimate the incidence of uveitis in a large, nationwide population-based cohort and identify specific clinical and treatment-related predictors of ocular inflammation. Methods: This retrospective cohort study utilised electronic health records from Clalit Health Services, Israel's largest health maintenance organization (2002-2024). We identified 157,360 patients with dermatologist-confirmed psoriasis and 156,927 age- and sex-matched controls. The primary outcome was incident uveitis, with risk estimated using Cox proportional hazards models. Within the psoriasis cohort, multivariable logistic regression was employed to identify predictors of uveitis, ensuring appropriate temporal sequencing between psoriasis treatment exposure and outcome. Results: Over a median follow-up of 12.6 years, psoriasis was associated with a significantly higher risk of incident uveitis (adjusted Hazard Ratio [aHR] 1.80; 95% CI, 1.50-2.15). Stratified analysis revealed a graded risk pattern: mild psoriasis showed no increased risk (aHR 1.01; 95% CI, 0.91-1.13), whereas severe disease (aHR 1.59; 95% CI, 1.25-2.03) and concomitant SpA (aHR 2.21; 95% CI, 1.87-2.61) demonstrated markedly elevated risks. Within the psoriasis cohort, independent predictors included SpA, diabetes mellitus, systemic lupus erythematosus, and sarcoidosis. Exposure to biologics, particularly etanercept (OR 3.37; 95% CI, 2.42-4.54), was associated with higher odds of uveitis, potentially reflecting higher disease severity. Conclusions: Incident uveitis risk in psoriasis is primarily driven by the magnitude of systemic inflammatory burden, with the highest risk observed in severe disease and those with concomitant SpA. Clinicians should maintain heightened vigilance for ocular symptoms in these high-risk subgroups to ensure timely intervention.

Weiterlesen

]]>493Sat, 28 Feb 2026 14:57:08 +0000Long-term osteoprotective effects of IL-17A blockade with secukinumab in psoriatic arthritis: data from the PSARTROS-II study.https://www.psoriasis-news.de/articles.html/1_articles/long-term-osteoprotective-effects-of-il-17a-blockade-with-secukinumab-in-psoriatic-arthritis-data-from-the-psartros-ii-study-r492/ObjectiveTo evaluate the long-term efficacy of interleukin (IL)-17A inhibition with secukinumab on structural bone changes and clinical outcomes in psoriatic arthritis (PsA).

Methods

We conducted a phase-IV non-interventional study on adult patients with active PsA using high-resolution peripheral quantitative CT (HR-pQCT) and MRI of the hand over 48 months. All participants received secukinumab treatment and were followed up according to clinical practice, with repeated HR-pQCT and MRI. Number and volume of erosions, bone density, cortical and trabecular microarchitecture and bone biomechanical properties were assessed based on HR-pQCT scans. MRI synovitis, tenosynovitis, osteitis, periarticular inflammation, erosions and osteoproliferation were quantified by Psoriatic Arthritis MRI Score (PsAMRIS)-Outcome Measures in Rheumatology (OMERACT) score. Study outcomes included drug survival and changes from baseline in disease activity, functional status and imaging-detected inflammation and damage.

Results

32 patients with PsA (40.6% female, mean age 56±7.5 years) were enrolled. Drug survival rate was 68.8% at 48 months. Secukinumab was highly effective in all PsA disease domains, with significant improvements in Disease Activity Score 28 (p<0.001), Leeds Enthesitis Index (p=0.027), Psoriasis Area and Severity Index (p=0.001), C reactive protein (p=0.09), Psoriatic Arthritis Impact of Disease (p<0.001) and pain (p<0.001). Functional status measured by the Health Assessment Questionnaire remained stable. On HR-pQCT, bone density, microarchitecture and biomechanics were preserved. There was no progression of bone erosions (all changes were not significant). On MRI, PsAMRIS erosion and osteoproliferation subitems increased marginally (+1.4 and +0.8, respectively), while inflammatory changes remained stably low. No major safety signals emerged.

Conclusion

Multimodal imaging with HR-pQCT and MRI showed no relevant progression of structural bone damage over 48 months in patients with PsA treated with secukinumab, suggesting that anti-IL-17A therapy induces sustained osteoprotective effects in PsA.

Weiterlesen

]]>492Sat, 28 Feb 2026 14:57:08 +0000Photosensitive psoriasis mimicking cutaneous lupus erythematosus: a case report.https://www.psoriasis-news.de/articles.html/1_articles/photosensitive-psoriasis-mimicking-cutaneous-lupus-erythematosus-a-case-report-r491/Weiterlesen

]]>491Sat, 28 Feb 2026 14:57:08 +0000Assessing Targeted Proteomics in Inflammatory Skin Diseases with the Tape-stripping Method.https://www.psoriasis-news.de/articles.html/1_articles/assessing-targeted-proteomics-in-inflammatory-skin-diseases-with-the-tape-stripping-method-r490/® Target Inflammation panel: (i) all 8 tape strips (1-8) from 1 skin site and from the other skin site, (ii) the first 4 tape strips (1-4), and (iii) the next 4 tape strips (5-8). Biomarkers were above the detection limit for 65.7% of atopic dermatitis, 70.2% of psoriasis, and 45.1% of contact dermatitis samples. There were no significant differences in biomarker levels between the use of 4 or 8 tape strips, or between the first and last 4 tape strips. In general, atopic dermatitis and psoriasis patients were distinguishable from controls, whereas contact dermatitis patients were not. Based on the overall data quality, analysing protein signatures in tape strips with the targeted inflammatory panel is feasible.

Weiterlesen

]]>490Sat, 28 Feb 2026 14:57:08 +0000Perspectives and Real-World Clinical Practice of Portuguese Dermatologists on Biologic Dose Spacing in Psoriasis: Results from a Nationwide Survey.https://www.psoriasis-news.de/articles.html/1_articles/perspectives-and-real-world-clinical-practice-of-portuguese-dermatologists-on-biologic-dose-spacing-in-psoriasis-results-from-a-nationwide-survey-r489/IntroductionBiologic therapies have transformed the management of moderate-to-severe psoriasis but are associated with long-term treatment burden and substantial healthcare costs. Dose spacing, defined as extending dosing intervals in patients with controlled disease, has emerged as a potential optimization strategy. However, data on real-world implementation and clinician perspectives remain limited.

Methods

We conducted a national, cross-sectional survey among Portuguese dermatologists experienced in prescribing biologic therapies for psoriasis. An anonymous, web-based questionnaire assessed clinicians' perspectives and real-world practices regarding biologic dose spacing, including eligibility criteria, preferred biologic classes, implementation strategies, outcomes after loss of disease control, and limiting clinical factors.

Results

Seventy-five dermatologists completed the survey (response rate 48.4%). All respondents considered dose spacing feasible. The most frequently cited eligibility criteria were absolute Psoriasis Area and Severity Index (PASI) ≤ 1, body surface area (BSA) ≤ 1%, and a 90% improvement in PASI (PASI 90). Interleukin-23 (IL-23) inhibitors were perceived as the most suitable class for dose spacing (93.3%). In routine practice, dose spacing was applied frequently by 30.7% of respondents and occasionally by 48.0%. Most clinicians (69.3%) required more than 12 months of sustained disease control before initiating dose spacing, predominantly using progressive extension of dosing intervals (96.0%). IL-23 inhibitors were the biologics most frequently dose-spaced in current practice. Following loss of disease control, 86.7% reported successful recapture of response after reintroduction of standard dosing. The main factors limiting dose spacing were a history of difficult-to-control psoriasis (77.3%) and concomitant psoriatic arthritis (72.0%).

Conclusion

Biologic dose spacing is already integrated into clinical practice in Portugal. Further prospective studies are needed to establish standardized criteria and guide safe implementation.

Weiterlesen

]]>489Sat, 28 Feb 2026 14:57:08 +0000From static pathology to dynamic immunity: immunological plasticity and histopathological remodeling in atopic dermatitis and psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/from-static-pathology-to-dynamic-immunity-immunological-plasticity-and-histopathological-remodeling-in-atopic-dermatitis-and-psoriasis-r488/No abstract supplied.

Weiterlesen

]]>488Sat, 28 Feb 2026 14:57:08 +0000